All In Biotech

Drug Trial Radar · NCT05970510

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Participants With Generalized Anxiety Disorder.

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 555 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

555

Actual

Start

Aug 4, 2023

Primary completion

Jul 31, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
Luye Pharma Group Ltd.Industry
Sponsor type
Industry
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to evaluate the efficacy and safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets compared to placebo in adults participants with generalized anxiety disorder over a period of 8 weeks.

Conditions

  • Generalized Anxiety Disorder

Interventions

  • Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mgDrug

    orally once a day

  • Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mgDrug

    orally once a day

  • placeboDrug

    orally once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Hamilton Anxiety(HAMA) Rating Scale total score at endpointTime frame: from baseline to week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Sixth Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.